Drug Database
CL

clobetasol (clobetasol, Mipharm / Dermovate / Dermoval)

✓ Approved

Pierre Fabre S.A. · NR3C1 · 小分子

什么是 clobetasol?

clobetasol 是一种小分子,由Pierre Fabre S.A.研发。该药已获批,用于治疗相关适应症,给药途径:Topical。

药物档案

商品名clobetasol, Mipharm, Dermovate, Dermoval
公司Pierre Fabre S.A.
药物类别小分子
分子靶点NR3C1
给药途径Topical
状态Approved

作用机制

分子靶点

clobetasol 作用于 1 个分子靶点:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

clobetasol 针对 4 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersDermatitis allergic✓ Approved
Skin and subcutaneous tissue disordersDermatitis atopic✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved
Skin and subcutaneous tissue disordersSeborrhoeic dermatitis✓ Approved

相关研究文献

PubMedBMC cardiovascular disorders2026-11-19

Heterogeneity in diagnosing heart failure - real world data from electronic health records.

Roine Liis L, Kasepalu Teele T, Loorents Helene H, Elmet Märt M et al.

Heart failure (HF) prevalence is increasing and is relatively well described. Less is known about using tests in diagnosing HF in clinical practice. The aim of this article was to describe the diagnostic practices among incident HF patients in Estonia. Electronic health records and healthcare provision claims from 1st January 2012 to 31st December 2019 for a random sample of 10% of the Estonian population (N = 150 824) were used to retrieve data about newly diagnosed HF patients focusing on natriuretic peptide and echocardiographic testing. The incident HF was defined as the first occurrence of International Statistical Classification of Diseases and Related Health Problems 10th Revision codes I50.x or I11.0, with no occurrence of I50.x or I11.0 during the previous four years. The group differences were analysed using the Wilcoxon rank sum test for continuous variables. For categorical variables, the chi-square test and binary logistic regression, controlled for gender and age, were used. Within one year before and after the HF diagnosis, 31.0% of patients underwent echocardiography and natriuretic peptide testing, but 40.7% did not receive either investigation. Most diagnostic assessments were performed in three months before HF diagnosis with 41% of patients receiving at least one test. We observed that patients diagnosed with HF in emergency departments were most likely to undergo at least one HF test (81,3%). In clinical practice, HF may be diagnosed in the absence of sufficient diagnostic evidence. By highlighting key shortcomings in the routine clinical diagnosis of HF, this study underscores the potential to enhance patient care (e.g. creating HF pathways).

PMID 43052775
阅读全文 →
PubMedCardiovascular diabetology2026-11-19

Diabetes and all-cause mortality in a national telemonitored heart failure cohort: role of comorbidities, heart failure etiology burden, and short-term weight variability.

Valensi Paul P, Esser Rémi R, Picard François F, Jagu Annabelle A et al.

Diabetes mellitus is common in patients with heart failure (HF) and is associated with worse outcomes. However, its prognostic role in real-world telemonitored HF populations remains insufficiently characterized. We evaluated the association between diabetes and all-cause mortality in a national telemonitored HF cohort while considering HF severity, comorbidities, HF etiology burden, and short-term weight variability (WV). We conducted a retrospective cohort study of adults enrolled in the French Satelia® Cardio telemonitoring program between 2018 and 2024 (NCT07561866). Baseline clinical characteristics, HF etiologies, comorbidities, and repeated weight measurements were analyzed. Short-term WV was defined as the mean absolute 10-day weight change per patient and categorized according to the cohort median. Survival was assessed using Kaplan-Meier analyses and multivariable Cox proportional hazards models. Among 16,556 patients (mean age 74.9 ± 12.9 years; 64% male), 4,723 (28.5%) had diabetes. Median follow-up was 13 months in patients with diabetes and 11 months in those without diabetes; 2,266 patients died (13.7%). Patients with diabetes more frequently had ischemic and hypertensive HF etiologies, obesity and greater HF etiology burden. In multivariable models without NYHA class, diabetes was independently associated with higher mortality, with a significant diabetes-by-age interaction suggesting a stronger association among patients aged < 75 years. After adjustment for NYHA class in the smaller subgroup, this association was attenuated and no longer statistically significant. Male sex, clinician-reported renal failure, combined chronic obstructive pulmonary disease and sleep apnea syndrome, and higher NYHA class were associated with higher mortality, whereas obesity was associated with lower mortality. Individual HF etiologies were not consistently associated with mortality across adjusted models, whereas increasing HF etiology burden remained associated with higher mortality. High short-term WV was associated with poorer survival. In this large national telemonitored HF cohort, the association between diabetes and mortality was attenuated after accounting for HF severity assessed by NYHA class. Mortality was more consistently associated with HF severity, comorbidities and cumulative HF etiology burden than with individual HF etiologies. Short-term WV emerged as an exploratory telemonitoring-derived marker associated with poorer survival. These findings support a multidimensional approach to risk assessment in patients with diabetes.

PMID 43053091
阅读全文 →
PubMedEuropean heart journal. Valvular and structural heart disease2026-11-19

Changes in loop diuretic use following mitral valve surgery for mitral regurgitation according to age: a nationwide cohort study.

Melchior Simon E SE, Schöps Liv B LB, Petersen Jeppe K JK, Carranza Christian L CL et al.

Loop diuretic use (LDU) may provide complementary information on post-operative heart failure (HF) burden after mitral valve surgery (MVS). We investigated changes in LDU before and after MVS for mitral regurgitation (MR) and assessed post-operative HF admission according to age. Using Danish nationwide registries, we identified patients aged ≥18 years discharged after first-time MVS for MR between 1996 and 2022. LDU was assessed from redeemed prescriptions before surgery and at post-operative landmarks. HF admission within 5 years was estimated with death as a competing risk. Among 6840 patients, LDU was 46.2% before surgery and declined among survivors to 27.0% at 12-15 months and 23.7% at 36-39 months. Pre-operative use was more frequent with increasing age, ranging from 27.9% in patients aged 18-49 years to 64.3% in those aged ≥80 years. Postoperatively, LDU remained common, ranging from 13.5% to 41.6% at 12-15 months and from 11.9% to 35.4% at 36-39 months across age groups. The 5-year cumulative incidence of HF admission was 20.9% (95% CI: 20.0-22.0%) overall and increased across age groups, from 13.9% to 27.4%. Pre-operative LDU was associated with higher 5-year mortality irrespective of recorded HF status. LDU declined after MVS for MR but remained common, particularly among older patients, and showed an age-related pattern consistent with hospital admission for HF.

PMID 43053869
阅读全文 →
PubMedJournal of the American Chemical Society2026-11-19

Carbon Monoxide-Releasing Nanoreactors Transiently Modulate TLR4 Signaling to Resolve Inflammation.

Gan Guihai G, Yin Dalong D, Zhou Zuotao Z, Dong Haoyang H et al.

Uncontrolled inflammation drives diverse acute and chronic diseases, yet effective suppression without compromising host defense remains a major therapeutic challenge. Although carbon monoxide (CO) is an endogenous gasotransmitter with well-established anti-inflammatory activity, its clinical translation has been limited by the lack of delivery systems capable of controlling dose, release kinetics, and tissue localization. Here, we report a metal-free micellar nanoreactor that implements a nanoconfined cascade between endoperoxides (EPOs) and 3-hydroxyflavone (3-HF) derivatives for sustained CO generation. Thermal decomposition of EPOs continuously produces singlet oxygen (1O2), which subsequently oxidizes adjacent CO precursors to release CO with programmable kinetics under physiological conditions. Systematic molecular screening revealed that the cascade kinetics are governed by the structures of the EPOs as well as aromatic-ring extension and chalcogen substitution within the 3-HF scaffold, enabling oxidation rates to be tuned over 3 orders of magnitude. Relative to an equivalent mixture of separately assembled micelles, coassembly accelerated S-HF oxidation and enhanced anti-inflammatory activity, consistent with more efficient capture of the short-lived 1O2 intermediate within the micellar core. Sustained intracellular CO generation transiently decreased surface-detectable TLR4/MD-2, attenuated downstream inflammatory signaling and cytokine amplification, and promoted macrophage repolarization, while TLR4/MD-2 levels subsequently returned toward baseline. The nanoreactors alleviated inflammation and tissue injury in mouse models of APAP-induced acute liver injury, LPS-induced endotoxemia, and allergic airway inflammation. These findings establish an autonomous, nanoconfined reaction cascade for sustained gasotransmitter delivery and transient modulation of pathological inflammation.

PMID 43053409
阅读全文 →
PubMedEuropean heart journal. Valvular and structural heart disease2026-11-19

Prognostic impact of tricuspid regurgitation improvement after transcatheter mitral valve replacement: results from an international multicentre registry.

von der Heide Ina I, Scotti Andrea A, Coisne Augustin A, Strotmann Lena L et al.

Tricuspid regurgitation (TR) frequently coincides with severe mitral regurgitation (MR). Transcatheter mitral valve replacement (TMVR) effectively eliminates MR and may secondarily affect TR severity. This study aimed to assess incidence and prognostic value of TR improvement after TMVR using data from an international multicentre registry. Patients with symptomatic MR and baseline TR undergoing TMVR from the CHoice of OptImal transCatheter trEatment for Mitral Insufficiency international multicentre registry were analysed. Tricuspid regurgitation improvement was defined as a ≥1-grade TR reduction at discharge. The primary endpoint was all-cause mortality or heart failure (HF) hospitalization at 1 year. Stepwise Cox regression was performed to assess the adjusted prognostic impact of TR improvement. Among 309 patients (median age 77 years), TR improvement occurred in 33.0% after TMVR. Patients with TR improvement were younger, had higher European System for Cardiac Operative Risk Evaluation II, less coronary artery disease, and lower baseline tricuspid annular plane systolic excursion. Mitral regurgitation was durably eliminated in most patients, irrespective of TR evolution. At 1 year, there was no statistically significant difference in all-cause mortality or HF hospitalization between patients with and without TR improvement (27.0% vs 36.9%; P = .14). Following stepwise Cox regression, TR improvement was an independent predictor of all-cause mortality or HF hospitalization 1 year after TMVR (hazard ratio 0.45, 95% confidence interval 0.23-0.88; P = .02). TR improvement occurs frequently following TMVR and is associated with favourable 1-year outcomes. These results support the clinical relevance of concomitant TR and the systematic assessment of TR after TMVR.

PMID 43053866
阅读全文 →
PubMedEuropean heart journal. Valvular and structural heart disease2026-11-19

Prognostic value of algorithm-based invasive haemodynamic assessment of paravalvular regurgitation after transcatheter aortic valve replacement with self-expanding devices-the APPOSE registry.

Stens Niels A NA, Versteeg Geert A A GAA, Rooijakkers Maxim J P MJP, Zegers Erwin E et al.

Detecting and grading paravalvular regurgitation (PVR) following transcatheter aortic valve replacement (TAVR) remains challenging. We evaluated the prognostic value of algorithm-based invasively measured haemodynamic indices of PVR for all-cause mortality and heart failure (HF) rehospitalizations. We included 727 patients who underwent TAVR with a self-expanding valve for severe native aortic stenosis between 2015 and 2021 at Radboudumc. Invasive left ventricular and aortic pressures were continuously measured and analysed offline using a validated algorithm for standardized computation of haemodynamic indices of PVR. The primary endpoint was an event-adjudicated composite of all-cause mortality and HF rehospitalization across 3-year follow-up. Algorithm-derived diastolic pressure-time index (DPTI) ≤58 and diastolic delta (DD) ≤32 mmHg were independently associated with the composite outcome (hazard ratio [HR] 1.64 [95% confidence interval (CI): 1.14, 2.37], HR 1.80 [95% CI: 1.21, 2.68], respectively). Following stratification for angiography-graded PVR, algorithm-derived invasive indices remained independently associated with the composite outcome in those with angiographic mild-moderate (HR DPTI ≤58 mmHg: 2.94, 95% CI: 1.68, 5.15) but not none/trace PVR (HR DPTI ≤58 mmHg: 0.91, 95% CI: 0.49, 1.69). Inferences remained consistent when considering only those with angiographic mild PVR (HR DPTI ≤58: 3.19, 95% CI: 1.62, 6.26). Algorithm-based invasive assessment of PVR showed independent prognostic value for the risk of all-cause mortality and HF rehospitalization across 3-year follow-up. Additionally, following stratification for angiography-graded PVR, haemodynamic indices remained independently associated with the composite outcome in those with angiographic mild PVR. Together, this highlights the potential of real-time automated assessment of invasive haemodynamics for risk stratification of patients undergoing TAVR.

PMID 43053864
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多clobetasol